All In Biotech

Free tool

FAERS Monitor: Pifeltro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210806 or its brand name (Pifeltro, Doravirine). Reports on generic versions are filed under their own applications.

Reports

788

Serious

620

79% of reports

Hospitalization

198

Death reported

75

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anxiety71
  • pain71
  • emotional distress65
  • anhedonia53
  • death53
  • chronic kidney disease48
  • drug resistance43
  • pathogen resistance42
  • nausea41
  • drug ineffective38
  • treatment noncompliance37
  • off label use34
  • virologic failure34
  • renal failure33
  • product dose omission issue32

Reports by year received

View as table
YearReports
20101
20111
20165
20186
201949
202079
2021113
2022121
2023146
2024112
202590
202665

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,371 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
virologic failureSignal34169.8122.15,505
pathogen resistanceSignal42123.692.04,963
anhedoniaSignal5353.941.62,699
drug resistanceSignal4344.833.51,795
treatment noncomplianceSignal3718.113.2581
chronic kidney diseaseSignal4816.912.8703
emotional distressSignal6514.311.4797
anxietySignal716.75.3340
renal failureSignal336.64.8153
painSignal713.12.5101
product dose omission issueSignal322.92.139
death531.61.313
nausea411.41.04
off label use341.00.70
drug ineffective380.80.63

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.